The aim of the research was to assess lipid-lowering and antiatherosclerotic effects of atorvastatin 20–40 mg daily in patients with coronary heart disease (CHD) and diabetes mellitus (DM) type 2 after coronary artery bypass grafting (CABG) during one year follow-up. The examination, including coronary angiography (CA), was performed before intervention and after 12 months. All patients received complex therapy, which included atorvastatin 40 mg. Retrospectively the patients were divided into three groups according to adherence to the treatment. The first group included patients who took treatment continuously, the second with an average compliance, the third group – who stopped receiving therapy. Fifteen percent of patients didn’t not follow recommendations for lipid-lowering therapy, 54% patients adhered to some degree, 31% were highly compliant. Adherence to treatment with atorvastatin at a dose of 20–40 mg was associated with optimization of lipid profile and slowering of coronary atherosclerosis progression according to the CA data. Progression of coronary atherosclerosis was registered in 100% of non-compliant patients, against 76% who were moderately compliant and 42% – with high compliance. Revealed changes prove the necessity of adherence to treatment to reduce the risk of cardiovascular complications in patients with CHD and DM type 2 after CABG.